BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22572213)

  • 21. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
    Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
    Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
    Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    Cassier PA; Thevenet C; Walter T; Baulieux J; Scoazec JY; Bancel B; Adham M; Souquet JC; Ponchon T; Lombard-Bohas C
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1111-7. PubMed ID: 20386107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
    Wentrup R; Winkelmann N; Mitroshkin A; Prager M; Voderholzer W; Schachschal G; Jürgensen C; Büning C
    Gut Liver; 2016 May; 10(3):470-5. PubMed ID: 26814610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
    Wirasorn K; Ngamprasertchai T; Khuntikeo N; Pakkhem A; Ungarereevittaya P; Chindaprasirt J; Sookprasert A
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1885-91. PubMed ID: 23829232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
    Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
    Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.
    Schweitzer N; Weber T; Kirstein MM; Fischer M; Kratzel AM; Reineke-Plaaß T; Lehner F; Manns MP; Vogel A
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1347-1355. PubMed ID: 28314929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    Ishii M; Itano O; Morinaga J; Shirakawa H; Itano S
    PLoS One; 2022; 17(4):e0266707. PubMed ID: 35452492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
    Ann Oncol; 2004 May; 15(5):770-4. PubMed ID: 15111345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma.
    Chen SC; Chen MH; Li CP; Chen MH; Chang PM; Liu CY; Tzeng CH; Liu YM; Yen SH; Chao Y; Huang PI
    Hepatogastroenterology; 2015; 62(137):102-7. PubMed ID: 25911877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
    Lee SY; Kim HS; Choi YJ; Park KH; Shin SW; Kim YH; Tae Kim S
    Am J Ther; 2016; 23(6):e1449-e1455. PubMed ID: 25285672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
    Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
    Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
    Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
    Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
    Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study.
    Choe JW; Kim HJ; Kim JS
    Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):153-156. PubMed ID: 31974040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
    Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
    Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
    Iqbal S; Rankin C; Lenz HJ; Gold PJ; Ahmad SA; El-Khoueiry AB; Messino MJ; Holcombe RF; Blanke CD
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1595-602. PubMed ID: 21556747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.